The emerging target KRAS G12C in genitourinary malignancies

被引：0
|
作者：
Grivas, Petros
Necchi, Andrea
Bratslavsky, Gennady
Shapiro, Oleg
Jacob, Joseph
Elvin, Julia Andrea
Vergilio, Jo-Anne
Killian, Keith
Williams, Erik
Ramkissoon, Shakti H.
Severson, Eric Allan
Hemmerich, Amanda
Schrock, Alexa Betzig
Chung, Jon
McGregor, Kimberly
Reddy, Prasanth
Alexander, Brian Michael
Sokol, Ethan
Danziger, Natalie
Ross, Jeffrey S.
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[5] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
434
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation
    Fraissenon, Antoine
    Bayard, Charles
    Morin, Gabriel
    Benichi, Sandro
    Hoguin, Clement
    Protic, Sanela
    Zerbib, Lola
    Ladraa, Sophia
    Firpion, Marina
    Blauwblomme, Thomas
    Naggara, Olivier
    Duruisseaux, Michael
    Delous, Marion
    Boitel, Clothilde
    Bringuier, Pierre-Paul
    Payen, Lea
    Legendre, Christophe
    Kaltenbach, Sophie
    Balducci, Estelle
    Villarese, Patrick
    Asnafi, Vahid
    Bisdorff, Annouk
    Guibaud, Laurent
    Canaud, Guillaume
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 334 - 342
  • [42] ONCOGENIC KRAS G12C MUTATION DERIVED INHIBITOR DEVELOPMENT
    Leveles, Ibolya
    Koppany, Gergely
    Nyiri, Kinga
    Vertessy, G. Beata
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : E117 - E117
  • [43] Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
    Zeng, Mei
    Lu, Jia
    Li, Lianbo
    Feru, Frederic
    Quan, Chunshan
    Gero, Thomas W.
    Ficarro, Scott B.
    Xiong, Yuan
    Ambrogio, Chiara
    Paranal, Raymond M.
    Catalano, Marco
    Shao, Jay
    Wong, Kwok-Kin
    Marto, Jarrod A.
    Fischer, Eric S.
    Janne, Pasi A.
    Scott, David A.
    Westover, Kenneth D.
    Gray, Nathanael S.
    CELL CHEMICAL BIOLOGY, 2017, 24 (08): : 1005 - +
  • [44] KRAS G12C inhibition with sotorasib in metastatic colorectal cancer
    Severi, Christophe
    Van Cutsem, Eric
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (08) : 2792 - 2795
  • [45] KRAS G12C Inhibitors: New Drugs, A New Hope
    Singhal, Surbhi
    Schokrpur, Shiruyeh
    Gandara, David
    Riess, Jonathan W.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) : 1594 - 1598
  • [46] Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation
    Chen, Yuxi
    Hua, Chen
    Lin, Xiaoxi
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1259 - 1260
  • [47] Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down
    Hobbs, G. Aaron
    Wittinghofer, Alfred
    Der, Channing J.
    CANCER CELL, 2016, 29 (03) : 251 - 253
  • [48] Concurrent inhibition of KRAS G12C and ERK1/2 overcomes acquired resistance to KRAS G12C inhibitors (G12Cis) conferred by various genetic alterations
    Wang, W.
    Lim, S. M.
    Yu, M. R.
    Cho, B. C.
    Chen, C.
    Wu, W.
    Zhang, J.
    Chen, Z. J.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S118 - S118
  • [49] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Fukui, Sarina
    Sawada, Ryo
    Tachibana, Yusuke
    Matsui, Yohei
    Nakamura, Ryota
    Ishida, Masaki
    Kawachi, Hayato
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Furuya, Naoki
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Nishioka, Naoya
    Horinaka, Mano
    Sakai, Toshiyuki
    Uehara, Hisanori
    Yano, Seiji
    Son, Bo-Kyung
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER LETTERS, 2024, 587
  • [50] KRAS G12C as a Target of Naringenin for Inducing Cell Death in NCI-H23 Cells
    Patar, Abani Kumar
    Kma, Lakhon
    Barman, Jitul
    Ghosh, Shekhar
    Baruah, Taranga Jyoti
    PHARMACOGNOSY RESEARCH, 2022, 14 (03): : 256 - 262
12345